Form 4: Cingulate Inc. Executive Receives Stock Options as Part of 2024 Bonus

Laurie Myers, EVP and COO of Cingulate Inc., was granted stock options as part of her 2024 bonus.

Summary

• Laurie Myers, the Executive Vice President and Chief Operating Officer of Cingulate Inc., received 9,319 stock options as part of her 2024 bonus.
• The stock options have an exercise price of $4.76 per share.
• The options were granted on January 17, 2025, and are exercisable from that date until January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally positive for aligning management with shareholder interests. There are no indications of negative sentiment.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders.
• The options serve as an incentive for the executive to contribute to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, although specific terms can vary based on company performance and individual agreements.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company performance.
• The executive benefits from the potential future value of the stock options.

Key Dates

Keywords

stock options, executive compensation, insider trading, Cingulate Inc., Laurie Myers, EVP, COO